论文信息 - Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2015 - 字舞流文

Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2015

H. Rollag | J. Lennerstrand | K. Bragstad | S. Dudman | A. Kanestrøm | A. Kran | K. Stene-Johansen | J. Pettersson | I. Litleskare | B. M. Bergersen

[1] T. Asselah,et al. Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection , 2018, The New England journal of medicine.

[2] M. Manns,et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection , 2017, The New England journal of medicine.

[3] T. Berg,et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. , 2015, The New England journal of medicine.

[4] K. Reddy,et al. GrazoprevirElbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection , 2015, Annals of Internal Medicine.

[5] Robert Herring,et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.

[6] J. Pawlotsky. New hepatitis C therapies: the toolbox, strategies, and challenges. , 2014, Gastroenterology.

[7] Anna Persson,et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. , 2012, The New England journal of medicine.